Abstract Details

Title Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer's disease

Topic Aging and Dementia

Presentation(s) S2 - (-)

Poster/Presentation
Number 003

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Sebastian F. Von Rosenstiel, MD, PhD (Takeda) PRESENTER	No disclosure on file
Sarah Gheuens, MD	No disclosure on file
Tianle Chen, PhD	Dr. Chen has received personal compensation for serving as an employee of Biogen.
	No disclosure on file
Ping Chiao, MD (Biogen Idec)	No disclosure on file
	No disclosure on file
Christian Von Hehn, MD, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
Roger Nitsch, MD (University of Zurich, Division of Psychiatry)	No disclosure on file
Samantha Budd Haeberlein	Samantha Budd Haeberlein has received personal compensation for serving as an employee of Biogen. An immediate family member of Samantha Budd Haeberlein has received personal compensation for serving as an employee of Alkermes. Samantha Budd Haeberlein has received stock or an ownership interest from Biogen.
Alfred W. Sandrock, MD, PhD (Biogen)	No disclosure on file